Literature DB >> 14735128

Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential.

Christina R Maxwell1, Yuling Liang, Bryanne D Weightman, Stephen J Kanes, Ted Abel, Raquel E Gur, Bruce I Turetsky, Warren B Bilker, Robert H Lenox, Steven J Siegel.   

Abstract

Auditory evoked potentials have been used in a variety of animal models to assess information-processing impairments in schizophrenia. Previous mouse models have primarily employed a paired click paradigm to assess the transient measures of auditory gating. The current study uses stimulus trains at varied interstimulus intervals (ISI) between 0.25 and 8 s in mice to assess the effects of chronic olanzapine and haloperidol on auditory processing. Data indicate that olanzapine increases the amplitude of the N40, P80, and P20/N40 components of the auditory evoked potential, whereas haloperidol had no such effect. The ISI paradigm also allowed for an evaluation of several components of the mouse evoked potential to assess those that display response properties similar to the human P50 and N100. Data suggest that the mouse N40 displays an ISI response relationship that shares characteristics with the human N100, whereas the P20 appears more consistent with the human P50 across the ISI range evaluated in this task. This study suggests that olanzapine may help improve N100 impairments seen in schizophrenia, while haloperidol does not.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14735128     DOI: 10.1038/sj.npp.1300376

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  25 in total

1.  Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients.

Authors:  C R Maxwell; Y Liang; M P Kelly; S J Kanes; T Abel; S J Siegel
Journal:  Neuroscience       Date:  2006-06-05       Impact factor: 3.590

2.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

Review 3.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

4.  NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia.

Authors:  John A Saunders; Michael J Gandal; Steve J Siegel
Journal:  Neurobiol Dis       Date:  2012-01-09       Impact factor: 5.996

5.  Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors.

Authors:  Kenji Hashimoto; Masaomi Iyo; Robert Freedman; Karen E Stevens
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

6.  Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.

Authors:  Noam D Rudnick; Andrew A Strasser; Jennifer M Phillips; Christopher Jepson; Freda Patterson; Joseph M Frey; Bruce I Turetsky; Caryn Lerman; Steven J Siegel
Journal:  Nicotine Tob Res       Date:  2010-04-15       Impact factor: 4.244

7.  Event-related oscillations in mice: effects of stimulus characteristics.

Authors:  Cindy L Ehlers; Jose R Criado
Journal:  J Neurosci Methods       Date:  2009-05-03       Impact factor: 2.390

Review 8.  Animal models and measures of perceptual processing in schizophrenia.

Authors:  Steven J Siegel; John C Talpos; Mark A Geyer
Journal:  Neurosci Biobehav Rev       Date:  2013-07-15       Impact factor: 8.989

9.  The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components.

Authors:  Patrick M Connolly; Christina Maxwell; Yuling Liang; Jonathan B Kahn; Stephen J Kanes; Ted Abel; Raquel E Gur; Bruce I Turetsky; Steven J Siegel
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 10.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.